Investor Presentaiton

Appendix <Contents> FY2022 Financial Results (Full Basis) Main Events/Targets for FY2022 Product Launch Target P.21 P.22 FY2022 Financial Position P.23 R&D P.24 R&D P.25 R&D P.26 R&D P.27 R&D P.28 R&D Sumitomo Pharma Regenerative Medicine/Cell Therapy Launched Product and Development Pipeline Product Launch Target (Frontier Business) New Chemical Entity: DSP-2342 New Chemical Entity: SP-101 © Sumitomo Pharma Co., Ltd. All Rights Reserved. 20

View entire presentation